• FDA probes hospitalizations tied to fake Ozempic

    The FDA is investigating reports of hospitalizations tied to suspected counterfeit versions of semaglutide drugs, including three in the U.S., according to records from the agency's adverse event reporting system. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Fill out this short survey here and attend our annual meeting for free.
  • Kaiser calls union's ask of 43% raise 'not reasonable'

    As hundreds of pharmacy and imaging workers for Kaiser Permanente strike, a spokesperson for the system told CBS affiliate KPIC their union's ask for a 43% raise over the next four years is "frankly, not reasonable."
  • 2nd choice drug reduced C. diff infections by 45%

    Pneumonia patients who took an antibiotic that's typically reserved as an alternative were less likely to develop Clostridioides difficile infections compared to those taking the recommended drug, according to a study from Veterans Affairs Hospitals. 
  • Pharmacists treating hypertension patients could save US $1.1 trillion: Study

    The U.S. healthcare industry could save more than $1.1 trillion and prevent about 15 million heart attacks over the next 30 years if pharmacists were more involved in hypertension care, according to research conducted by Virginia Commonwealth University in Richmond. 
  • 340B Health, ASHP chide CMS' final payment rules

    Organizations representing thousands of hospital pharmacies are criticizing CMS' plan to not provide further reimbursement to 340B hospitals after paying a $9 billion lump sum. 
  • FDA puts clinical hold on cancer drug study

    Nurix Therapeutics, a drugmaker based in San Francisco, said the FDA has placed a partial clinical hold on its phase 1 trial for an experimental drug for lymphoma and leukemia. 
  • The pharmacists who revealed the myth of 'decongestants'

    Sixteen years after pharmacists from the University of Florida College of Pharmacy in Gainesville petitioned the FDA to require new efficacy studies of an ingredient in decongestants, their efforts came to fruition. In September, an FDA panel unanimously declared the ingredient ineffective. 
  • Intermountain pushes into drone drug delivery

    Salt Lake City-based Intermountain Health is one of the latest health systems to enter the emerging world of prescription delivery via drone. 
  • Phase 3 drug study finds 'unprecedented' positive results

    A global study of zoliflodacin, a drug candidate for gonorrhea, found "unprecedented" phase 3 results, its drugmaker said Nov. 1. 
  • CVS announces 2nd wave of layoffs

    In August, CVS said it would cut about 5,000 jobs, and a few weeks later, its workforce was notified of layoffs in at least nine states. Before Halloween, the retail chain filed more WARN notices. 
  • Some clinicians could over-administer Moderna's COVID-19 shot, FDA warns

    The FDA is advising healthcare workers who administer Moderna's COVID-19 pediatric vaccine to only administer 0.25 milliliters instead of the entire vial. 
  • Why staffing is pharmacy leaders' No. 1 concern

    As the three-day walkouts among CVS, Walgreens and Rite Aid pharmacy employees come to a close, hospital pharmacy leaders shared with Becker's their workforce concerns. 
  • A quiet 'pharmageddon' walkout

    There's been no way to confirm how many pharmacists and pharmacy technicians have participated at planned walkouts at CVS, Rite Aid and Walgreens locations nationwide, though estimates and reports suggest a quiet turnout. 
  • Hospitals are searching for more pharmacists this year

    Compared to 2022, there is a 15% higher demand for hospital pharmacists so far in 2023, according to a recent report from the American Association of Colleges of Pharmacy. 
  • Pfizer to close New Jersey site, relocate nearly 800 workers

    Pfizer is shuttering its location in Gladstone, N.J., and the company is offering to relocate the current employees.
  • Cleveland Clinic to employ drug-delivery drones

    Cleveland Clinic is the latest health system to invest in drones that deliver prescription medications to patients' homes. 
  • An estimated 4,500 participating in CVS, Walgreens walkouts: 5 updates

    Organizers estimate as many as 4,500 pharmacists and pharmacy technicians at CVS, Rite Aid and Walgreens are participating in a three-day walkout that began Oct. 30.
  • American Pharmacists Association CEO calls for change amid Walgreens, CVS walkouts

    Michael Hogue, PharmD, CEO and executive vice president of the American Pharmacists Association, has issued a statement of support for the planned walkouts by Walgreens and CVS pharmacy employees that began Oct. 30. 
  • Another Ozempic side effect pops up: 5 updates

    The FDA label for Ozempic does not mention muscle pain, but some patients taking the popular Type 2 diabetes drug for weight loss are experiencing the side effect, according to an Oct. 27 report in women's magazine First for Women.
  • FDA advisers favorable to 1st CRISPR gene therapy

    A panel of FDA advisers concluded after hours of discussion Oct. 31 that the first CRISPR gene therapy candidate is safe enough for clinical use, The New York Times reported. 

Featured Whitepapers

Featured Webinars